Aditxt Inc (ADTX)

$0.00 -0.01 (-75.79%)
Market Cap 8,000.00
Revenue (ttm) 3,195.00
Net Income (ttm) -41.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 362,990,313
Avg Vol 302,860,438
Day's Range N/A - N/A
Shares Out 816,000.00
Stochastic %K 0%
Beta 0.84
Analysts Strong Buy
Price Target $61.00

Company Profile

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 870 1200
Address:
2569 Wyandotte Street, Suite 101, Mountain View, United States
Auxmaul
Auxmaul Aug. 24 at 3:17 PM
$ADTX Do not sell yet
0 · Reply
NatureBoyRonFlair
NatureBoyRonFlair Aug. 24 at 3:16 PM
$ADTX liquide zone 0,06 $ Don't worry
0 · Reply
Bakhm
Bakhm Aug. 24 at 3:15 PM
$ADTX ignite next,come back soon
0 · Reply
Fjam
Fjam Aug. 24 at 3:13 PM
$ADTX yes
0 · Reply
Bakhm
Bakhm Aug. 24 at 3:13 PM
$ADTX
0 · Reply
Vision1988
Vision1988 Aug. 24 at 3:11 PM
$ADTX Everybody ho seling now. You will bay bakc in September just at a higer prices MOCHI higher
0 · Reply
Fjam
Fjam Aug. 24 at 3:11 PM
$ADTX .0066 32 percent. StockTwits lagging
0 · Reply
Emergency123
Emergency123 Aug. 24 at 3:10 PM
$ADTX Adding another 100k tomorrow! Penny minimum .01 Proper squeeze (MOON)!
0 · Reply
Emergency123
Emergency123 Aug. 24 at 3:09 PM
$ADTX
0 · Reply
Vision1988
Vision1988 Aug. 24 at 3:09 PM
$ADTX Not seling a single share
0 · Reply
Latest News on ADTX
Why Is Penny Stock Aditxt (ADTX) Up Today?

2026-06-18T13:30:09.000Z - 2 months ago

Why Is Penny Stock Aditxt (ADTX) Up Today?

Aditxt signs agreement valuing Ignite Proteomics at $150M

2026-06-09T11:50:09.000Z - 2 months ago

Aditxt signs agreement valuing Ignite Proteomics at $150M

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Jun 9, 2026, 7:45 AM EDT - 2 months ago

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Jun 8, 2026, 8:15 AM EDT - 2 months ago

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Aditxt appoints Busch as interim CEO

2026-06-01T15:05:46.000Z - 3 months ago

Aditxt appoints Busch as interim CEO

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Jun 1, 2026, 8:15 AM EDT - 3 months ago

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Aditxt announces 1-for-27 reverse stock split

2026-05-14T16:21:02.000Z - 3 months ago

Aditxt announces 1-for-27 reverse stock split

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

May 14, 2026, 8:15 AM EDT - 3 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Aditxt announces publication featuring Ignite Proteomics subsidiary

2026-04-20T12:30:43.000Z - 4 months ago

Aditxt announces publication featuring Ignite Proteomics subsidiary

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Apr 20, 2026, 8:15 AM EDT - 4 months ago

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Aditxt files to sell 148.28M shares of common stock for holders

2026-04-13T10:11:46.000Z - 4 months ago

Aditxt files to sell 148.28M shares of common stock for holders

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Mar 19, 2026, 8:15 AM EDT - 5 months ago

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Aditxt acquires Ignite Proteomics in $36M transaction

2026-03-13T12:55:13.000Z - 5 months ago

Aditxt acquires Ignite Proteomics in $36M transaction

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Mar 13, 2026, 8:15 AM EDT - 5 months ago

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Aditxt to effect 1-for-8 reverse split of common stock

2026-03-05T14:03:50.000Z - 6 months ago

Aditxt to effect 1-for-8 reverse split of common stock

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Mar 5, 2026, 8:30 AM EST - 6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

3 Penny Stocks to Watch Now, 12/2/25

2025-12-02T16:19:00.000Z - 9 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM KTTA

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Nov 18, 2025, 8:00 AM EST - 9 months ago

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Aditxt begins enrollment in Mitomic Endometriosis Test study

2025-10-27T13:00:25.000Z - 10 months ago

Aditxt begins enrollment in Mitomic Endometriosis Test study

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 27, 2025, 8:30 AM EDT - 10 months ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Evofem Announces Voting Results from Special Meeting of Stockholders

Oct 20, 2025, 4:19 PM EDT - 10 months ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 11, 2025, 9:18 AM EDT - 1 year ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Sep 9, 2025, 9:28 AM EDT - 1 year ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 25, 2025, 9:15 AM EDT - 1 year ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 21, 2025, 8:56 AM EDT - 1 year ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 19, 2025, 9:39 AM EDT - 1 year ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 14, 2025, 8:46 AM EDT - 1 year ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 11, 2025, 8:30 AM EDT - 1 year ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aug 5, 2025, 8:46 AM EDT - 1 year ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 29, 2025, 9:00 AM EDT - 1 year ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 22, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 15, 2025, 9:12 AM EDT - 1 year ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 26, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Aditxt files to sell up to 50M shares of common stock for holders

2025-06-20T21:15:06.000Z - 1 year ago

Aditxt files to sell up to 50M shares of common stock for holders

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 11, 2025, 8:14 AM EDT - 1 year ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Aditxt appoints Evofem CEO Saundra Pelletier to board

2025-06-09T12:20:54.000Z - 1 year ago

Aditxt appoints Evofem CEO Saundra Pelletier to board

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 9, 2025, 8:15 AM EDT - 1 year ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Jun 5, 2025, 8:15 AM EDT - 1 year ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt announces termination of arrangement agreement with Appili Therapeutics

2025-05-19T12:11:08.000Z - 1 year ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 1 year ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

May 2, 2025, 9:00 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 17, 2025, 8:15 AM EDT - 1 year ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 16, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 14, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 11, 2025, 8:15 AM EDT - 1 year ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Apr 2, 2025, 8:15 AM EDT - 1 year ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 28, 2025, 8:15 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 17, 2025, 8:15 AM EDT - 1 year ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Mar 6, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 21, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Feb 13, 2025, 8:15 AM EST - 1 year ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 1 year ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Auxmaul
Auxmaul Aug. 24 at 3:17 PM
$ADTX Do not sell yet
0 · Reply
NatureBoyRonFlair
NatureBoyRonFlair Aug. 24 at 3:16 PM
$ADTX liquide zone 0,06 $ Don't worry
0 · Reply
Bakhm
Bakhm Aug. 24 at 3:15 PM
$ADTX ignite next,come back soon
0 · Reply
Fjam
Fjam Aug. 24 at 3:13 PM
$ADTX yes
0 · Reply
Bakhm
Bakhm Aug. 24 at 3:13 PM
$ADTX
0 · Reply
Vision1988
Vision1988 Aug. 24 at 3:11 PM
$ADTX Everybody ho seling now. You will bay bakc in September just at a higer prices MOCHI higher
0 · Reply
Fjam
Fjam Aug. 24 at 3:11 PM
$ADTX .0066 32 percent. StockTwits lagging
0 · Reply
Emergency123
Emergency123 Aug. 24 at 3:10 PM
$ADTX Adding another 100k tomorrow! Penny minimum .01 Proper squeeze (MOON)!
0 · Reply
Emergency123
Emergency123 Aug. 24 at 3:09 PM
$ADTX
0 · Reply
Vision1988
Vision1988 Aug. 24 at 3:09 PM
$ADTX Not seling a single share
0 · Reply
Rotarypower1972
Rotarypower1972 Aug. 24 at 3:08 PM
$ADTX guys selling for Pennie’s when you can have dollars
1 · Reply
vestorlest
vestorlest Aug. 24 at 3:06 PM
$ADTX their website directed me to a virus website?
1 · Reply
MrSchultz
MrSchultz Aug. 24 at 3:02 PM
$ADTX This is the only news I found https://www.stocktitan.net/sec-filings/ADTX/8-k-aditxt-inc-reports-material-event-3d7e2ec269d0.html https://www.sec.gov/Archives/edgar/data/1726711/000121390026091703/ea0302612-8k_aditxt.htm
0 · Reply
EZGREENMONEY
EZGREENMONEY Aug. 24 at 3:02 PM
$ADTX
0 · Reply
NatureBoyRonFlair
NatureBoyRonFlair Aug. 24 at 2:58 PM
$ADTX yahoo Mountain dew
0 · Reply
DancingQueen69
DancingQueen69 Aug. 24 at 2:56 PM
$ADTX Buying under 0.004$ was a frustrating job. You couldn't buy in bigger batches not to interrupt algos. But we made it. Now it's time to enjoy and let it go back to cents.
0 · Reply
Vision1988
Vision1988 Aug. 24 at 2:54 PM
$ADTX 🚨 $ADTX IS MOVING AGAIN TODAY! The momentum is back — and this is exactly where things can get interesting. 📈 We’ve already seen what $ADTX can do when buyers step in. Now the key is whether today’s strength can attract even more volume and attention. Don’t chase blindly, but don’t ignore the move either. 👀 Volume + momentum + attention = a setup worth watching. $ADTX #ADTX #SmallCaps #Momentum #Stocks
0 · Reply
Fjam
Fjam Aug. 24 at 2:53 PM
$ADTX i remember $SHMP my first stock ever. Bought 100k at .005 ish it ran to .98 7 years ago.
0 · Reply
Guestthatrader
Guestthatrader Aug. 24 at 2:53 PM
$ADTX a lot of short got wipe out at the .005 levels
0 · Reply
krispiecritter
krispiecritter Aug. 24 at 2:51 PM
$ADTX We are moving! Finally! Why?
1 · Reply
trt102967
trt102967 Aug. 24 at 2:49 PM
$ADTX Slow and steady for the next 2-3 weeks
0 · Reply
Luvdagame1
Luvdagame1 Aug. 24 at 2:49 PM
$ADTX idiots selling for pennies🙄😒
2 · Reply